![CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Syndicated Broadcast Covering Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin [Video Edition]](https://s3.castbox.fm/08/8c/c3/c6d9b7540a5b422af977632cc3dccbd8e8_scaled_v1_400.jpg "CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Syndicated Broadcast Covering Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin [Video Edition]")
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Syndicated Broadcast Covering Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin [Video Edition]
Description
CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently announced the recommendation of the independent Data Safety Monitoring Board (DSMB) that the Company’s ongoing global, potentially pivotal trial of the investigational agent, Berubicin for the treatment of glioblastoma multiforme (GBM) continue without any modification.
The recommendation follows the DSMB’s pre-specified futility analysis of unblinded (to the DSMB only) efficacy and safety data in the Company’s trial of Berubicin versus Lomustine, a standard of care in patients with recurrent GBM. More specifically, the DSMB reviewed the primary endpoint of overall survival (OS) and secondary efficacy measures progression-free survival (PFF) and overall response rate (ORR), as well as safety data in evaluable patients. In order to support continuing the trial, Berubicin’s efficacy had to be at least comparable to Lomustine’s on the primary endpoint (OS).
To read the original press release, visit: https://www.nnw.fm/Sj7iP
Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
United States
